Extensive keloids had high wound dehiscence after postoperative radiotherapy
Wound dehiscence occurred in 78% of extensively involved keloid sites versus 5% of simple lesions after surgery and postoperative RT.
Wound dehiscence occurred in 78% of extensively involved keloid sites versus 5% of simple lesions after surgery and postoperative RT.
Surgery provided substantially better local control in T3–T4a N0–N1 laryngeal cancer, while disease-specific survival remained similar and CRT preserved laryngeal function in 79%.
Treatment discontinuation was 25.0% with pre-RT cachexia versus 4.6% without, with approximately sixfold higher adjusted odds.
Short-course EBRT plus endorectal HDR brachytherapy produced 80% cCR/ncCR, but grade 3 late rectal toxicity occurred in 27%.
HYPO-RT-PC showed persistently poor agreement between patient- and clinician-reported toxicity, particularly for urinary and bowel symptoms.
Routine treatment CBCT detected skeletal muscle loss that independently tracked worse survival in 337 patients with HPV-positive oropharyngeal cancer.
A systematic review argues that α/β is disease- and context-specific rather than a fixed biological constant across radiotherapy settings.
Kidney proton SBRT modeling supported 4-mm superior–inferior and 3-mm lateral/anterior–posterior positioning uncertainty with intrafraction repositioning.
Among long-term NPC survivors treated with IMRT, radiation-related second malignancy incidence reached 6.66% at 15 years.
In the randomized OPEN trial, SGRT-supported open masks maintained setup accuracy while reducing distress and improving treatment experience.
Personalized Bayesian heart-dose limits improved identification of NSCLC patients at low risk of treatment-related cardiac troponin elevation.
Concurrent durvalumab with either 60 Gy/15 or 60 Gy/30 was feasible in a 24-patient phase I study without concurrent chemotherapy.
Nine prospective rectal and anal re-irradiation trials varied widely in dose, margins, cumulative-dose methods, organs at risk, and PRO reporting.
IPTW-weighted response was 71.1% versus 37.6%, with median survival 23.0 versus 15.6 months after adding SBRT.
Failure-free survival was 96.6% at 12 months, while grade 3 GU toxicity increased to 12.5% by one year.